Astellas Pharma's sales FY 2017, by region

This statistic depicts the sales revenue of the Japanese pharmaceutical company Astellas Pharma Inc. in fiscal year 2017, broken down by region. During the measured period, the consolidated sales value of Astellas Pharma amounted to approximately 1.31 trillion yen. The highest value was generated in the Americas, with sales amounting to approximately 433 billion Japanese yen.

Sales revenue of Astellas Pharma Inc. in fiscal year 2017 (in billion Japanese yen), by region

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

September 2018

Region

Japan

Survey time period

fiscal year 2017; the company's fiscal year starts on April 1 of the stated year and ends on March 31 of the following year

Special properties

sales by geographical area are calculated according to the location of sellers

Supplementary notes

1 Japanese yen equals 0.00881 U.S. dollars or 0.00778 euros as of December 2018.

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 / Month *
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract; Prices do not include sales tax.

Statistics on "Pharmaceutical trends in Europe"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.